62
Participants
Start Date
June 29, 2020
Primary Completion Date
November 14, 2023
Study Completion Date
November 14, 2023
STK-001 - Single Ascending Doses
Experimental : Single Ascending Doses - STK-001 drug product is an antisense oligonucleotide administered as an intrathecal injection. Four dose levels will be evaluated ( 10mg, 20mg,30mg, 45mg and 70mg ).
STK-001 - Multiple Ascending Doses
Experimental : Multiple Ascending Doses - STK-001 drug product is an antisense oligonucleotide administered as an intrathecal injection. Three dose levels will be evaluated ( 20mg,30mg and 45mg ).
NYU Comprehensive Epilepsy Center, New York
Children's Hospital of Philadelphia, Philadelphia
Children's National Medical Center, Washington D.C.
AdventHealth Orlando, Orlando
Nicklaus Children's Hospital, Miami
Le Bonheur Children's Hospital, Memphis
University of Michigan - Mott Children's Hospital, Ann Arbor
University of Iowa Hospitals and Clinics; Pediatric Specialty Clinic, Iowa City
Mayo Clinic, Rochester
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Cook Children's Health Care System, Fort Worth
Children's Hospital Colorado, Aurora
Primary Children's Hospital, Salt Lake City
UCSF Benioff Children's Hospital, San Francisco
Oregon Health & Science University, Portland
Seattle Children's Hospital, Seattle
Multicare Institute for Research and Innovation, Tacoma
Massachusetts General Hospital - Pediatric Epilepsy Program, Boston
Stoke Therapeutics, Inc
INDUSTRY